ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

COG Cambridge Cognition Holdings Plc

48.50
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 48.50 48.00 49.00 48.50 48.50 48.50 34,555 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 12.61M -409k -0.0117 -41.45 16.9M
Cambridge Cognition Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker COG. The last closing price for Cambridge Cognition was 48.50p. Over the last year, Cambridge Cognition shares have traded in a share price range of 48.40p to 104.00p.

Cambridge Cognition currently has 34,852,833 shares in issue. The market capitalisation of Cambridge Cognition is £16.90 million. Cambridge Cognition has a price to earnings ratio (PE ratio) of -41.45.

Cambridge Cognition Share Discussion Threads

Showing 101 to 121 of 900 messages
Chat Pages: Latest  12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
11/9/2014
08:57
Lots to get excited about except the current share price which hopefully will improve at some point. Finn Cap have reiterated their £1 target.
battlebus2
11/9/2014
07:26
Happy with the progress being made here...
playful
11/9/2014
07:25
Very happy with these results and the expected return to profitability in 2015,,,


Financial Highlights

-- Total revenue up 23.3% to GBP2.49m (H1 2013: GBP2.02m)
-- Adjusted* EBITDA reduced to GBP0.40m loss (H1 2013: GBP1.04m loss)
-- Loss before tax reduced to GBP0.47m (H1 2013: GBP1.49m loss)
-- Loss per share reduced to 2.9p (H1 2013: 14.4p)
-- Cash balances of GBP1.59m (31 Dec 2013: GBP2.26m)
* Adjusted for share-based payments and one-off H1 2013 IPO expenses

Commenting on the results Nick Kerton, Chief Executive Officer, said:

"Our results for the first half of the year demonstrate the Company's return to growth. We have worked hard over the last year to develop Cambridge Cognition into a commercially driven business and to establish a solid platform for future growth. This hard work is beginning to pay off and the first half performance gives us confidence that we will meet current expectations for the full year and that we are on track to deliver a profit in 2015."

battlebus2
03/7/2014
18:01
Heilium rising star fund has taken 3%.
battlebus2
03/7/2014
13:20
Moving up atleast :))
battlebus2
02/7/2014
17:41
1.7 million changing hands today at 47p, hopefully an overhang cleared or partially cleared.


hxxp://www.businessweekly.co.uk/biomedtech-/17174-cambridge-cognition-revenues-running-25-per-cent-ahead

battlebus2
02/7/2014
09:00
Amazing - decent trading update and not a single trade.
janeann
02/7/2014
08:05
Yes very positive janeann, seems there's a few shares to clear before we can move up.
battlebus2
02/7/2014
07:58
Looks very positive Battlebus; I do like their increasing involvement in clinical trials work and that this should deliver 'higher quality and predictable revenues'
janeann
30/6/2014
20:09
Might be off interest to those who hold.

hxxp://api.ning.com/files/ou2dKjFnSwtqGoxomUxLkhhvz1Lr9O3LiScCJ0zqzygdVBI7-9CyLjfrvKQNSVLOQ033ze1TA-B22akAVs2A0*wtQUAKY2jY/CambridgeCognitionPresentation20140625.pdf

investali
26/6/2014
20:47
Welcome onboard janeann.

Thanks to RicGains for his summary of last nights Sharesoc event posted on Fool.

Cambridge Cognition (COG)

Here we had a presentation from the CEO and a senior scientist from the company, which was useful as the company moves towards a more commercial focus. For example, the senior scientist spoke of "pediatric populations", I suspect the commercial CEO would have just called them "kids".

When pharma companies want to test a drug, its quite straightforward to test the effectiveness. The patient either turns blue/has the wound heal/explodes, or it doesn't work. It's harder to test whether someone's memory has improved or test if the drug has had a negative impact on mental function.

This company produce cognitive tests that can be used to test memory and other brain functions. The tests are non cultural and don't require language. They are used in three markets:

Academics - To quantify their theories. 1300 papers have been published using it, 400 in the last three months. (Lumpy revenue)

Clinical Trials - Drug companies need to prove that their drugs do work. (Reasonably consistent revenue)

Healthcare - When you go to your GP panicing that you forgot to lock your door this morning and that this is clear evidence of memory loss, there is a 75% chance that you are what is called "worried well". However, 25% of patients are experiencing a problem. It's difficult to know which is which - so they have developed an app that GP's can prescribe to test to see if there is a memory problem. (Growing revenue)

A lot of this software is now delivered by the cloud, and they kept talking about how things were moving that way. It also means that when someone comes with a specific request for a complex test, they can quickly build a unique recipe test, from about 25 different elements, which they just fuse together and make easily accessible to the client. The CEO likened it to building a custom product like you would a fancy coffee.

They stressed that they had a clear commitment not to go back to investors for money, unless there was an acquisition that would accelerate growth. Questions were raised about the unusual situation of floating and then having top level management change, almost straight away.

I notice today that there is an RNS out announcing a new contract.

Hopefully we'll now have a flood of corrections, clarifications and some analysis from smart accountants - but that is a very introductory flavour for you, I hope it's helpful. Thanks as ever to the organisers.

battlebus2
26/6/2014
10:38
well joined you hear this am after some deliberation. Like the new drug trials contract work and given the push for more work on neurological issues this should be a lucrative area for the business.
janeann
26/6/2014
08:05
thought we deserved a tick up on that news but no buyers at the minute it seems.
battlebus2
26/6/2014
07:33
Did anyone attend the sharesoc event last night or know of a write up anywhere.
battlebus2
26/6/2014
07:13
And I thought I was early :-)
cheshire man
19/6/2014
08:36
Hopefully we can benefit from the governments new focus on dementia to be announced today.
battlebus2
17/6/2014
12:14
COG are presenting at the ShareSoc growth company seminar on 25th June. See for details and to register. Only a few places left, so register ASAP if you'd like to attend!

Cheers,

Mark
Twitter @marben100, @ShareSocUK

marben100
16/6/2014
15:26
Very illiquid with only 20% in public hands and with no buyers the spread is widening with every sell.
battlebus2
06/6/2014
16:26
Beggars belief at times this stock market. Some selling on the good contract news but as ever this is a long game and I intend to see these trading At £1 plus.
battlebus2
06/6/2014
15:12
Seems to be a seller around to spoil the fun here.
battlebus2
05/6/2014
18:00
Thanks for the Finn cap note Cheshire Man, hopefully the Sharesoc presentation will bring us to the attention of a few more investors.
It's a shame we didn't finish the day blue.

battlebus2
Chat Pages: Latest  12  11  10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock